Zobrazeno 1 - 10
of 106
pro vyhledávání: '"Wan Li Liu"'
Publikováno v:
ACS Omega, Vol 8, Iss 45, Pp 42540-42547 (2023)
Externí odkaz:
https://doaj.org/article/ebd72887039a4881b57b315793b37e1b
Autor:
Su-Mei Xu, Li-Wen Chang, Cheng-Yuan Tsai, Wan-Li Liu, Dai Li, Shan-Shan Li, Xiao-Min Li, Ping-Sheng Xu
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: The cap-snatching mechanism of influenza virus mRNA transcription is strongly suppressed by TG-1000, a prodrug rapidly metabolized into TG-0527, is a potent cap-dependent nucleic acid endonuclease inhibitor. Herein, we aimed to assess the
Externí odkaz:
https://doaj.org/article/93d7d8d2d753474194ef26c05bd85fbc
Autor:
Yu Wang, Qi Huang, Wan-Li Liu, Meng Wu, Xiao-hui Li, Mu-Sheng Zeng, Ya-Xian Wu, Shan Xing, Bo-Yu Tian, Xue-Ping Wang, Xia He, Shu-Lin Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Immune checkpoint inhibitors (ICIs)-based treatments have been recommended as the first line for refractory recurrent and/or metastatic nasopharyngeal carcinoma (NPC) patients, yet responses vary, and predictive biomarkers are urgently nee
Externí odkaz:
https://doaj.org/article/74f817d61c9248b5aea970a755baff93
Autor:
Shi‐Bing Li, Yan‐Yan Liu, Li Yuan, Ming‐Fang Ji, Ao Zhang, Hui‐Yu Li, Lin‐Quan Tang, Shuo‐Gui Fang, Hua Zhang, Shan Xing, Man‐Zhi Li, Qian Zhong, Shao‐Jun Lin, Wan‐Li Liu, Peng Huang, Yi‐Xin Zeng, Yu‐Ming Zheng, Zhi‐Qiang Ling, Jian‐Hua Sui, Mu‐Sheng Zeng
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 9, Pp 1-19 (2020)
Abstract Metabolic reprogramming plays important roles in development and progression of nasopharyngeal carcinoma (NPC), but the underlying mechanism has not been completely defined. In this work, we found INSL5 was elevated in NPC tumor tissue and t
Externí odkaz:
https://doaj.org/article/621a29cd73654baba154f0c200991840
Autor:
Zhe Qiang, Zong-yuan Zhou, Ting Peng, Pu-zi Jiang, Nan Shi, Emmanuel Mfotie Njoya, Bahtigul Azimova, Wan-li Liu, Wei-hua Chen, Guo-lin Zhang, Fei Wang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 37, Iss 1, Pp 1-15 (2018)
Abstract Background Drugs that inhibit the MEK/ERK pathway have therapeutic benefit in bladder cancer treatment but responses vary with patients, for reasons that are still not very clear. Interferon-α (IFN-α) is also used as a therapeutic agent fo
Externí odkaz:
https://doaj.org/article/7378701b6d8647c5862510b9d26271f5
Autor:
Min-jie Mao, Ning Xue, Xue-ping Wang, Pei-dong Chi, Yi-jun Liu, Qi Huang, Shu-qin Dai, Wan-li Liu
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background To investigate the predictive value of chemokine CCL27 for identifying early stage nasopharyngeal carcinoma (NPC) patients within a population seropositive for Epstein-Barr virus (EBV) capsid antigen-specific IgA (VCA-IgA). Method
Externí odkaz:
https://doaj.org/article/4ac2348b9b4e4ab4a0262779be632fc7
Autor:
Xue-Feng, Zhong, Gan, Zhou, Su-Mei, Xu, Xiao-Min, Li, Ying, Xu, Wan-Li, Liu, Yan-Xin, Zhang, Lin-Cong, He, Qiu-Ying, Shen, Ping-Sheng, Xu
Publikováno v:
Clinical Pharmacology in Drug Development. 11:1308-1313
This study was designed to evaluate the bioequivalence of the newly developed delayed-release oral suspension (test) 40 mg esomeprazole magnesium compared to its marketed counterpart (40 mg; reference) in healthy adult Chinese subjects. We conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fbad022e4721472fb0b6ad68d967e3e
https://doi.org/10.1002/cpdd.1139
https://doi.org/10.1002/cpdd.1139
Autor:
You‐Xuan Wu, Xue‐Feng Zhong, Xiao‐Min Li, Wan‐Li Liu, Yan‐Xin Zhang, Qiu‐Ying Shen, Su‐Mei Xu, Ping‐Sheng Xu
Publikováno v:
Clinical Pharmacology in Drug Development.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98819182a610ac3c30a5f9d7891637df
https://doi.org/10.1002/cpdd.1269
https://doi.org/10.1002/cpdd.1269
Publikováno v:
Functional Ecology. 36:1137-1150
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::167c2bdca54550e01c61fdc7d1ed4140
https://doi.org/10.1111/1365-2435.14032
https://doi.org/10.1111/1365-2435.14032
Publikováno v:
Translational Oncology, Vol 8, Iss 6, Pp 497-503 (2015)
Preoperative serum lactate dehydrogenase (LDH) has been used as a prognostic indicator for patients with hepatocellular carcinoma (HCC) treated with sorafenib or undergoing transcatheter arterial chemoembolization, but its significance in predicting
Externí odkaz:
https://doaj.org/article/1de9db9fa94f4a848c84e8946c52b832